✦ LIBER ✦

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

✍ Scribed by Giovanni Palladini; Paola Russo; Andrea Foli; Paolo Milani; Francesca Lavatelli; Laura Obici; Mario Nuvolone; Silvia Brugnatelli; Rosangela Invernizzi; Giampaolo Merlini

Publisher: Springer
Year: 2011
Tongue: English
Weight: 93 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1244-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of patients with advanced card

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

✍ Giovanni Palladini; Paola Russo; Francesca Lavatelli; Mario Nuvolone; Riccardo A 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 90 KB

Thalidomide, dexamethasone and lovastati

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

✍ Marek Hus; Norbert Grzasko; Marta Szostek; Andrzej Pluta; Grzegorz Helbig; Dariu 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 218 KB

The efficacy and safety of bortezomib an

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens

✍ Giulia Benevolo; Alessandra Larocca; Massimo Gentile; Patrizia Pregno; Francesca 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Erratum to: pegylated liposomal doxorubi

Erratum to: pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients

✍ Gabriele Buda; Enrico Orciuolo; Sara Galimberti; Matteo Pelosini; Mario Petrini 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 47 KB

Thalidomide, dexamethasone, Doxil and Ve

Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma

✍ Massimo Offidani; Laura Corvatta; Claudia Polloni; Silvia Gentili; Anna Mele; Ri 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 293 KB